Okta, Inc. vs TransMedics Group Inc — how do they compare? Okta, Inc. trades at $136.54 (market cap $24.63B), while TransMedics Group Inc trades at $71.34 (market cap $2.57B). The key difference: Okta, Inc. is far larger — about 9.6× TransMedics Group Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| OKTA | TMDX | |
|---|---|---|
Market Cap | $24.63B | $2.57B |
Sector | Technology | Technology |
52-Week High | $154.62 | $150.42 |
52-Week Low | $62.93 | $61.99 |
Enterprise Value | $22.45B | $2.97B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Trailing returns across standard periods
Latest headlines on both assets
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →